Analysts See $-0.24 EPS for Calithera Biosciences, Inc. (CALA); Mason Capital Management Has Lifted By $5.10 Million Its Time Warner (TWX) Holding

February 17, 2018 - By Marie Mckinney

Mason Capital Management Llc increased Time Warner Inc (TWX) stake by 7.01% reported in 2017Q3 SEC filing. Mason Capital Management Llc acquired 50,000 shares as Time Warner Inc (TWX)’s stock rose 1.19%. The Mason Capital Management Llc holds 763,378 shares with $78.21M value, up from 713,378 last quarter. Time Warner Inc now has $74.39 billion valuation. The stock increased 0.40% or $0.38 during the last trading session, reaching $95.37. About 6.29M shares traded or 13.28% up from the average. Time Warner Inc. (NYSE:TWX) has risen 36.37% since February 17, 2017 and is uptrending. It has outperformed by 19.67% the S&P500.

Analysts expect Calithera Biosciences, Inc. (NASDAQ:CALA) to report $-0.24 EPS on March, 15.They anticipate $0.21 EPS change or 46.67% from last quarter’s $-0.45 EPS. After having $-0.17 EPS previously, Calithera Biosciences, Inc.’s analysts see 41.18% EPS growth. The stock increased 16.55% or $1.15 during the last trading session, reaching $8.1. About 3.52 million shares traded or 456.49% up from the average. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since February 17, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Among 40 analysts covering Time Warner Inc. (NYSE:TWX), 17 have Buy rating, 0 Sell and 23 Hold. Therefore 43% are positive. Time Warner Inc. had 121 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Market Perform” rating given on Thursday, November 5 by Wells Fargo. The firm has “Outperform” rating given on Friday, September 11 by Macquarie Research. On Thursday, December 22 the stock rating was maintained by FBR Capital with “Outperform”. The firm earned “Buy” rating on Thursday, November 17 by Moffett Nathanson. The stock of Time Warner Inc. (NYSE:TWX) earned “Buy” rating by M Partners on Friday, November 27. The firm has “Sector Perform” rating given on Monday, October 24 by RBC Capital Markets. The firm has “Hold” rating given on Thursday, February 1 by RBC Capital Markets. The stock of Time Warner Inc. (NYSE:TWX) earned “Hold” rating by Wells Fargo on Thursday, January 4. The stock of Time Warner Inc. (NYSE:TWX) earned “Hold” rating by Cowen & Co on Friday, October 27. The stock of Time Warner Inc. (NYSE:TWX) earned “Hold” rating by Loop Capital on Friday, November 17.

Since December 14, 2017, it had 0 insider purchases, and 2 sales for $2.50 million activity. OLAFSSON OLAF had sold 23,450 shares worth $2.11 million. Shares for $390,647 were sold by BARR WILLIAM P.

Investors sentiment decreased to 0.76 in 2017 Q3. Its down 0.09, from 0.85 in 2017Q2. It turned negative, as 66 investors sold TWX shares while 374 reduced holdings. 69 funds opened positions while 264 raised stakes. 586.69 million shares or 2.23% less from 600.08 million shares in 2017Q2 were reported. Tig Limited accumulated 2.62 million shares. Tradewinds Mgmt owns 1,258 shares for 0.07% of their portfolio. Colony Group Ltd Liability accumulated 109,735 shares. British Columbia Inv Corporation invested in 478,979 shares. E&G Advsr Limited Partnership reported 7,350 shares. Tci Wealth Advsr reported 2,971 shares or 0.15% of all its holdings. Groesbeck Inv Corporation Nj holds 3,094 shares or 0.23% of its portfolio. Blackrock Incorporated accumulated 0.23% or 44.95M shares. Omers Administration Corp holds 0.3% in Time Warner Inc. (NYSE:TWX) or 257,200 shares. Mkp Capital Mgmt Ltd Liability holds 19,000 shares or 0.24% of its portfolio. San Francisco Sentry Investment (Ca) holds 3,455 shares or 0.12% of its portfolio. Rafferty Asset Mgmt Ltd Liability Co invested 0.01% of its portfolio in Time Warner Inc. (NYSE:TWX). Quinn Opportunity Ltd Liability accumulated 693,400 shares. Investec Asset Mgmt holds 0.08% in Time Warner Inc. (NYSE:TWX) or 178,896 shares. Driehaus Capital Mngmt Ltd Liability reported 0.87% in Time Warner Inc. (NYSE:TWX).

Investors sentiment decreased to 1.22 in 2017 Q3. Its down 2.03, from 3.25 in 2017Q2. It turned negative, as 16 investors sold Calithera Biosciences, Inc. shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported. First Personal Finance stated it has 1,359 shares or 0% of all its holdings. Northern Trust Corporation holds 334,183 shares or 0% of its portfolio. Raymond James Financial Services holds 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA) for 17,000 shares. Pacad Inv Limited invested in 0.03% or 10,000 shares. Blackrock stated it has 2.10M shares or 0% of all its holdings. 15,177 were reported by State Board Of Administration Of Florida Retirement System. Renaissance Technology Ltd Limited Liability Company has 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA). Ameritas Inv Ptnrs Inc holds 0% or 2,688 shares in its portfolio. Edge Wealth invested in 1,800 shares or 0.01% of the stock. Ny State Common Retirement Fund accumulated 32,700 shares or 0% of the stock. Svcs Automobile Association holds 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA) for 48,750 shares. Macquarie Gru Ltd holds 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA) for 4,600 shares. Virtu Finance Ltd accumulated 17,614 shares. Wells Fargo Mn holds 33,742 shares or 0% of its portfolio. Vanguard Group has 1.10M shares for 0% of their portfolio.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $287.36 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>